The Cheng-Prusoff relationship: something lost in the translation

doi:10.1016/0165-6147(93)90070-Z

Trends in Pharmacological Sciences

Volume 14, Issue 3, March 1993, Pages 89-91

https://doi.org/10.1016/0165-6147(93)90070-Z Get rights and content

Abstract

For a variety of reasons, pharmacologists often construct ‘inhibition curves’ to evaluate antagonists rather than employing the more comprehensive ‘Schild analysis’. There is a widespread perception that it is only possible to derive antagonist K_b, values from such experiments via application of the Cheng-Prusoff equation, requiring knowledge of the agonist affinity at the receptor. In this article, Douglas Craig presents a practical examination of ‘inhibition curve’ methodology and demonstrates that it is a related equation requiring no knowledge of agonist affinity, rather than the Cheng-Prusoff equation, that affords theoretically valid estimates of antagonist K_bvalues from this technique.

References (7)

R.M. Eglen et al.
Life Sci.
(1989)
R.F. Furchgott
O. Arunlakshana et al.
Br. J. Pharmacol.
(1959)

There are more references available in the full text version of this article.

Cited by (128)

Nuclear Medicine Preclinical Research: The Role of Cell Cultures
2023, Seminars in Nuclear Medicine
Cell lines are essential in biomedical research due to their adaptability and precise simulation of physiological and pathophysiological conditions. Cell culture techniques have greatly advanced our understanding of biology in various fields and are widely regarded as a reliable and durable tool. Their diverse applications make them indispensable in scientific research. Radiation-emitting compounds are commonly used in cell culture research to investigate biological processes. Radiolabeled compounds are utilized to study cell function, metabolism, molecular markers, receptor density, drug binding and kinetics, as well as to analyze the direct interaction of radiotracers with target organ cells. This allows for the examination of normal physiology and disease states. The In Vitro system simplifies the study and filters out nonspecific signals from the In Vivo environment, leading to more specific results. Moreover, cell cultures offer ethical advantages when evaluating new tracers and drugs in preclinical studies. While cell experiments cannot entirely replace animal experiments, they reduce the need for live animals in experimentation.
Convergent cross-species pro-cognitive effects of RGH-235, a new potent and selective histamine H<inf>3</inf> receptor antagonist/inverse agonist
2022, European Journal of Pharmacology
Citation Excerpt :
Receptor binding isotherms and concentration/dose-response curves were analysed by nonlinear regression using Origin 6.0 (OriginLab Corp., Northampton, MA), Prism 5.0 (GraphPad Software Inc., La Jolla, CA, USA) or Statistica 8 (Dell) software; all programs gave identical results. From the IC50 values, inhibition constants (Ki) were calculated by the Cheng-Prusoff equation (Cheng and Prusoff, 1973); antagonist affinity (KB) values were calculated according to the formula described by Craig (1993). For [35S] GTPγS binding, raw data were first converted to specific binding, then stimulation % above basal values.
The histamine H₃ receptor is a favourable target for the treatment of cognitive deficits. Here we report the in vitro and in vivo profile of RGH-235, a new potent, selective, and orally active H₃ receptor antagonist/inverse agonist developed by Gedeon Richter Plc. Radioligand binding and functional assays were used for in vitro profiling. Procognitive efficacy was investigated in rodent cognitive tests, in models of attention deficit hyperactive disorder (ADHD) and in cognitive tests of high translational value (rat touch screen visual discrimination test, primate fixed-foreperiod visual reaction time task). Results were supported by pharmacokinetic studies, neurotransmitter release, sleep EEG and dipsogenia. RGH-235 displayed high affinity to H₃ receptors (K_i = 3.0–9.2 nM, depending on species), without affinity to H₁, H₂ or H₄ receptors and >100 other targets. RGH-235 was an inverse agonist ([³⁵S] GTPγS binding) and antagonist (pERK1/2 ELISA), showing favourable kinetics, inhibition of the imetit-induced dipsogenia and moderate effects on sleep-wake EEG. RGH-235 stimulated neurotransmitter release both in vitro and in vivo. RGH-235 was active in spontaneously hypertensive rats (SHR), generally considered as a model of ADHD, and revealed a robust pro-cognitive profile both in rodent and primate tests (in 0.3–1 mg/kg) and in models of high translational value (e.g. in a rodent touch screen test and in non-human primates). The multiple and convergent procognitive effects of RGH-235 support the view that beneficial cognitive effects can be linked to antagonism/inverse agonism of H₃ receptors.
Holistic Assessment of Compound Properties—In Vitro to In Vivo Pharmacology
2022, Comprehensive Pharmacology
Effective drug discovery relies on the considered deployment of screening assays from the outset of a project. Selected carefully, the data from screening assays can guide series optimization and give insight into the likely performance of compounds in a patient population. Established assays can provide information on a wide variety of compound properties, ranging from target affinity and functional assessment through to pharmacokinetic and toxicological properties, and with capacity on a scale from high-throughput plate formats down to isolated bespoke experiments. Selecting the assays in which to screen a compound at a given stage in a discovery project is a balance between resource cost and information value, and can have a profound impact on the pace and outcomes of the project. This article presents commonly evaluated properties, their physiological relevance, caveats to their interpretation, and the integration of in silico, in vitro and in vivo data to characterize the holistic profiles of discovery compounds and series.
Models for Lead Optimization
2022, Comprehensive Pharmacology
Lead optimization is the process by which the properties of initial hit molecules active at a given therapeutic target are improved until they meet a set of pre-determined criteria based on the therapeutic hypothesis. This process requires the rigorous determination of the pharmacological properties of these molecules, at least, at its later stages. In this article, I outline mathematical models and experimental designs which allow the determination of these properties, that is affinity, efficacy, allosteric cooperativity and binding kinetics. I also discuss the ways in which these parameters can be used to predict the activity of a compound in different experimental systems, in other words, how they can be used translationally.
Plasmin-mediated proteolysis of human factor IXa in the presence of calcium/phospholipid: Conversion of procoagulant factor IXa to a fibrinolytic enhancer
2020, Journal of Thrombosis and Haemostasis
Factor (F) IX/IXa inactivation by plasmin has been studied; however, whether plasmin converts FIXa to a fibrinolytic enhancer is not known.
Investigate plasmin proteolysis site(s) in FIXa that inactivates and transforms it into a fibrinolytic enhancer.
NH₂‐terminal sequencing, mass spectrometry analysis, and functional assays.
Plasmin in the presence of Ca²⁺/phospholipid (PL) rapidly cleaved FIXaβ at Lys316↓Gly317 to yield FIXaγ followed by a slow cleavage at Lys413↓Leu414 to yield FIXaδ. FIXaγ/FIXaδ migrated indistinguishably from FIXaβ in nondenaturing gel system indicating that C‐terminal residues 317‐415/317‐413 of heavy chain remain noncovalently associated with FIXaγ/FIXaδ. However, as compared with FIXaβ, FIXaγ or FIXaγ/FIXaδ (25‐75 mixture, 8‐hour/24‐hour incubation analysis by mass spectrometry) was impaired ~ 10‐fold in hydrolyzing synthetic substrate CBS 31.39 (CH3‐SO2‐D‐Leu‐Gly‐Arg‐pNA), ~ 30‐fold (~ 5‐fold higher K_m, ~ 6‐fold lower k_cat) in activating FX in a system containing Ca²⁺/PL, and ~ 650‐fold in a system containing Ca²⁺/PL and FVIIIa. Further, FIXaγ or FIXaγ/FIXaδ bound FVIIIa with ~ 60‐fold reduced affinity compared with FIXaβ. Additionally, in ligand blots, plasminogen or diisopropylfluorophosphate‐inhibited plasmin (DIP‐plasmin) bound FIXaγ and FIXaδ but not FIXaβ. This interaction was prevented by ε‐aminocaproic acid or carboxypeptidase B treatment suggesting that plasminogen/DIP‐plasmin binds to FIXaγ/FIXaδ through newly generated C‐terminal Lys316 and Lys413. Importantly, FIXaγ/FIXaδ mixture but not FIXaγ enhanced tissue plasminogen activator (tPA)‐mediated plasminogen activation in a concentration dependent manner. Similarly, FIXaγ/FIXaδ mixture but not FIXaγ enhanced tPA‐induced clot lysis in FIX‐depleted plasma.
Plasmin cleavage at Lys316↓Gly317 abrogates FIXaβ coagulant activity, whereas additional cleavage at Lys413↓Leu414 converts it into a fibrinolytic enhancer.
Exploration of the molecular architecture of the orthosteric binding site in the α4β2 nicotinic acetylcholine receptor with analogs of 3-(dimethylamino)butyl dimethylcarbamate (DMABC) and 1-(pyridin-3-yl)-1,4-diazepane
2015, European Journal of Medicinal Chemistry
Citation Excerpt :
Data from the binding experiments were fitted to the equation % Bound = 100% Bound/(1+([L]/IC50)n). Since the concentrations of [3H]epibatidine used in the binding experiments were lower than the KD values determined for the radioligands the respective receptors, it was deduced from the Cheng–Prusoff equation [44] that the Ki values for the compounds were similar to the obtained IC50 values. The concentration-response curves for agonists and concentration–inhibition curves for antagonists in the FLIPR Membrane Potential Blue assay were constructed based on the differences in the fluorescence units (△FU) between the maximal fluorescence levels recorded before and after addition of eight different concentrations of the various ligands.
X-ray crystal structures of acetylcholine binding proteins (AChBPs) have revealed two different possible extensions to the classical ligand binding pocket known to accommodate various nicotinic agonists. One of the pockets is limited in size while the other is of considerable dimensions and protrudes along the interfacial cleft between subunits. To probe these putative extensions in functional nicotinic acetylcholine receptors (nAChRs), elongated analogs of 3-(dimethylamino)butyl dimethylcarbamate (DMABC) and 1-(pyridine-3-yl)-1,4-diazepane were prepared and characterized pharmacologically at neuronal heteromeric nAChRs. Although the new analogs, relative to parent compounds, displayed lower binding affinities, functional characterization of selected compounds revealed that they had retained partial α4β2 nAChR agonist activity. The structure–activity relationship data did not indicate an upper limit to the size of substituents as would have been expected if the ligand was bound in the smaller pocket. The data were better in agreement with a binding mode in which substituents protrude along the interfacial cleft of the receptor. This was further supported by docking into a homology model of the α4-β2 nAChR interface and by surface plasmon resonance biosensor analysis of binding of the compounds to acetylcholine-binding proteins, where they exhibit preference for Lymnaea stagnalis ACh binding protein (Ls-AChBP) over the Aplysia california ACh binding protein (Ac-AChBP). These results suggest new opportunities for expanding chemical space in the development of partial agonist and may be of interest in relation to development of novel smoking cessation aids.

View all citing articles on Scopus

View full text

Trends in Pharmacological Sciences

PrinciplesThe Cheng-Prusoff relationship: something lost in the translation

Abstract

Life Sci.

Br. J. Pharmacol.

Principles
The Cheng-Prusoff relationship: something lost in the translation